

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number  
**WO 2004/024902 A1**

(51) International Patent Classification<sup>7</sup>: C12N 5/08, 5/10,  
A61K 48/00, 35/14

(74) Agents: HUGHES, E., John, L. et al.; Davies Collison  
Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).

(21) International Application Number:  
PCT/AU2003/001212

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
16 September 2003 (16.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2002952834 16 September 2002 (16.09.2002) AU

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE  
WALTER AND ELIZA HALL INSTITUTE OF MEDI-  
CAL RESEARCH [AU/AU]; 1G Royal Parade, Parkville,  
VIC 3052 (AU).

Published:  
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): STEPTOE, Ray-  
mond, John [AU/AU]; 89 Rushall Crescent, North  
Fitzroy, VIC 3068 (AU). HARRISON, Leonard, Charles  
[AU/AU]; 27 Park Street, St Kilda, VIC 3182 (AU).

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: A METHOD OF TREATING AN AUTOIMMUNE DISEASE

(57) Abstract: The present invention relates generally to a method for treating or ameliorating the symptoms of or reducing or otherwise minimizing the risk of development of an autoimmune disease such as but not limited to autoimmune diabetes. More particularly, the present invention relates to the use of genetically modified hemopoietic stem cells and/or hemopoietic progenitor cells which express genetic material encoding one or more autoantigens which give rise to antigen-presenting cells that induce immune tolerance and/or protective immunity. The present invention provides, therefore, a method for the treatment and/or prophylaxis of autoimmune disease conditions such as type 1 diabetes.



## A METHOD OF TREATING AN AUTOIMMUNE DISEASE

### BACKGROUND OF THE INVENTION

5

#### FIELD OF THE INVENTION

The present invention relates generally to a method for treating or ameliorating the symptoms of or reducing or otherwise minimizing the risk of development of an autoimmune disease such as but not limited to autoimmune diabetes. More particularly, the present invention relates to the use of genetically modified hemopoietic stem cells and/or hemopoietic progenitor cells which express genetic material encoding one or more autoantigens which give rise to antigen-presenting cells that induce immune tolerance and/or protective immunity. The present invention provides, therefore, a method for the treatment and/or prophylaxis of autoimmune disease conditions such as type 1 diabetes.

#### DESCRIPTION OF THE PRIOR ART

Bibliographic details of references provided in the subject specification are listed at the end of the specification.

Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

25

Insulin-dependent or type 1 diabetes is caused by a lack of insulin, due to autoimmune-mediated destruction of pancreatic islet  $\beta$  cells. Individuals with type 1 diabetes require regular insulin injections to control their blood glucose levels. Failure to treat individuals in this manner can lead to death.

30

A more long term treatment strategy is required with the prevention of the autoimmune

- 2 -

condition being the principal goal.

Pancreas transplantation is currently the only curative therapy for type 1 diabetes, but this is hampered by the requirement for potentially toxic, life-long immunosuppressive drugs  
5 and by the dearth of human donors.

Bone marrow (BM) or hematopoietic stem cell (HSC) transplantation has recently been used to treat clinically severe autoimmune disease (Burt *et al.*, *Blood* 99: 768-784, 2002). In pre-clinical animal models, effective treatment of spontaneous autoimmune disease  
10 requires transplantation of BM or HSC from disease-resistant strains. To date, this has been achieved by allogeneic BM transplantation (BMT) (Ikehara *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 7743-7747, 1985; LaFace and Peck, *Diabetes* 38: 894-901, 1989; El-Badri *et al.*, *Transplantation* 70: 870-877, 2000; Himeno and Good, *Proc. Natl. Acad. Sci. USA* 85: 2235-2239, 1998; Kirzner *et al.*, *Biol. Blood Marrow Transplant.* 6: 513-522, 2000)  
15 leading to full or mixed chimerism (Li *et al.*, *J. Immunol.* 156: 380-388, 1996; Kaufman *et al.*, *J. Immunol.* 158: 2435-2442, 1997). However, the requirement for cytotoxic conditioning of the host and the risk of graft rejection (Castro-Malaspina *et al.*, *Blood* 99: 1943-1951, 2002) or graft-versus-host disease (Ratanatharathorn *et al.*, *Bone Marrow Transplant* 28: 121-129, 2001) render this approach unsuitable for widespread clinical  
20 application.

There is a need, therefore, to develop alternative strategies and approaches which prevent the development of autoimmune diabetes as well as other autoimmune disease conditions.

## SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the  
5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Targeting antigen to resting antigen-presenting cells (APCs), such as B cells, dendritic cells, epithelial cells or macrophages amongst others, is proposed as a means of inducing  
10 immunological unresponsiveness (tolerance) and/or protective immunity. As all immune cells are derived from hemopoietic stem cells (HSCs) and hemopoietic progenitor cells (HPCs), it is proposed, in accordance with the present invention, that HSCs and/or HPCs encoding an autoantigen will develop into APCs expressing the autoantigen. These are then used as an antigen-specific therapy to prevent autoimmune disease. Transplantation  
15 of syngeneic HSCs and/or HPCs avoids the need for conditioning regimens in a host and represents a novel, safe and effective strategy for preventing or treating autoimmune disease conditions.

With respect to autoimmune diabetes, proinsulin is proposed to be the key autoantigen.  
20

In accordance with the present invention, therefore, syngeneic transplantation of HSCs and/or HPCs encoding proinsulin enables proinsulin expression in resting APCs and this results in the prevention of the development of autoimmune diabetes. This is a safe and effective antigen-specific strategy applicable to autoimmune diabetes as well as other  
25 autoimmune conditions.

Accordingly, the present invention contemplates a method for preventing or otherwise reducing the risk of development and/or reducing the severity of an autoimmune-mediated condition in an animal or avian species. The method involves collecting HSCs and/or  
30 HPCs either from the animal or avian species to be treated or from a compatible donor, genetically modifying some or all of the HSCs and/or HPCs such that they express genetic

- 4 -

material encoding one or more autoantigens associated with the particular autoimmune disease and introducing these into the animal or avian species to be treated. Presentation of the autoantigen by APCs is proposed to induce T cell unresponsiveness or tolerance and/or protective immunity. The HSCs and/or HPCs may be collected from bone marrow  
5 or isolated from peripheral blood, cord blood or other convenient sites such as the liver. Once genetically modified, the cells are generally infused into the subject such that they enter the peripheral blood. This route of administration includes infusion or introduction to the liver such as *via* the portal vein.

10 In one embodiment, therefore, the present invention contemplates a method for generating an antigen presenting cell (APC) which presents an autoantigen associated with an autoimmune disease, the method comprising collecting a sample of hemopoetic stem cells (HSCs) and/or hemopoetic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding the autoantigen under conditions  
15 wherein the genetic material is expressed so that the HSCs and/or HPCs produce the autoantigens.

In a preferred embodiment, the autoimmune disease or condition is type 1 diabetes. The present invention extends, however, to a range of autoimmune diseases. With respect to  
20 autoimmune diabetes, the preferred autoantigen is proinsulin or an antigenic fragment or portion thereof.

The most preferred animal is a human but the present invention extends to other primates as well as livestock animals, laboratory test animals, companion animals, captured wild  
25 animals and avian species such as caged (aviary) birds, poultry birds and game birds.

The present invention provides kits in multiple compartmental form, the kit comprising a first compartment adapted to receive a source of HSCs and/or HPCs from a subject; a second compartment adapted to contain genetic material encoding an autoantigen;  
30 optionally a third or more compartments adapted to contain reagents wherein the kit comprises instructions for use comprising in a method comprising collecting a sample of

- 5 -

hemopoetic stem cells (HSCs) and/or hemopoetic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding the autoantigen under conditions wherein the genetic material is expressed so that the HSCs and/or HPCs produce the autoantigens.

- 6 -

A list of abbreviations used herein is provided in Table 1.

**TABLE 1**  
*Abbreviations*

5

ABBREVIATION	DESCRIPTION
APC	antigen presenting cell
BM	bone marrow
BMT	bone marrow transplantation
CD	cluster differentiation antigens
DC	dendritic cells
F2.5	FCS (2.5% v/v)
FCS	fetal calf serum
G	GM-CSF
G + T	mixture of GM-CSF and TGF $\beta$ 1
GM-CSF	granulocyte macrophage colony stimulating factor
HPC	hemopoietic progenitor cell
HSC	hemopoietic stem cell
i.v.	intravenous
iDC	immature dendritic cells
IL-10	interleukin 10
MHC	major histocompatibility complex
MLR	mixed lymphocyte reaction
NOD mice	non-obese diabetic mice
NOD-PI mice	NOD-transgenic proinsulin mouse
OVA	ovalbumin
PBL	peripheral blood leukocytes
PI	proinsulin
s.c.	subcutaneous
SD	standard deviation
T	TGF $\beta$ 1
TGF $\beta$ 1	transforming growth factor $\beta$ 1
T1D	type 1 diabetes

## BRIEF DESCRIPTION OF THE FIGURES

**Figure 1** is a graphical representation showing that transplantation of NOD-PI BM inhibits diabetes development. (A) Diabetes incidence was significantly reduced in recipients of NOD-PI BM (▼) compared to NOD BM (▲) ( $P=0.003$ ) or untreated NOD mice (■) ( $P=0.001$ ). NOD BM recipients did not differ from untreated controls. Data are pooled from two experiments in which BMT from NOD-PI or NOD mice was performed in parallel. (B) Diabetes incidence was significantly reduced in recipients of T cell-depleted NOD-PI BM (▼) compared to T cell-depleted NOD BM (▲) ( $P=0.003$ ) or untreated NOD mice (■) ( $P=0.036$ ). NOD BM recipients did not differ from untreated controls. Data are pooled from three experiments in which BMT from NOD-PI or NOD mice was performed in parallel.

**Figure 2** presents micrographic and graphical representations showing that transplantation of T cell-depleted NOD-PI BM prevents insulinitis but not sialitis. (A) Islets free of inflammatory infiltrate (insulitis) were common in recipients of NOD-PI BM and infiltration, when present, was restricted to the periphery of islets (arrow). (B) Extensively infiltrated islets (\*) were common in recipients of NOD BM. (C) Insulitis was significantly reduced in recipients of T cell-depleted NOD-PI BM (▲) compared to NOD BM (▼) cells ( $P = 0.008$ ). Data for age-matched NOD (■) and NOD-PI (◆) mice are included for comparison. (D) The number of sublingual gland inflammatory foci (sialitis score) did not differ between BMT and untreated mice. Individual mouse scores are pooled from two experiments in which BMT from NOD and NOD-PI mice was performed in parallel (horizontal bar indicates mean).

25

**Figure 3** presents graphical representations showing that transfer of NOD-PI hematopoietic stem cells (HSC) or hematopoietic progenitor cells (HPC) prevents diabetes development. (A) diabetes incidence was significantly reduced in recipients of NOD-PI HSC (▼) compared to recipients of NOD HSC (▲) ( $P=0.019$ ) or untreated NOD mice (■) ( $P=0.029$ ). NOD HSC recipients and untreated NOD mice did not differ significantly. (B) Diabetes incidence was significantly reduced in recipients of NOD-PI HPC (▼) compared

30



to recipients of NOD HPC (▲) ( $P=0.035$ ) or untreated NOD mice (■) ( $P=0.021$ ). NOD HPC recipients and untreated NOD mice did not differ significantly. Data are from one (A) or two (B) experiments in which BMT from NOD-PI and NOD mice was performed in parallel.

5

Figure 4 provides a graphical representation and tabulated data showing reconstitution of peripheral blood leucocytes (PBL) in recipients of T cell-depleted NOD or NOD-PI BM. (A) PBL were markedly depleted at 10-14 days but reconstituted by 8 weeks after irradiation and BMT in both NOD (▼) and NOD-PI (▲) T cell-depleted BM recipients, compared to untreated age-matched NOD mice (■). (B) PBL subsets in recipients of T cell-depleted BM from NOD or NOD-PI donors reconstituted similarly and were similar to age-matched NOD controls. Data are mean  $\pm$  SD from two experiments in which BMT from NOD and NOD-PI mice were performed in parallel.

Figure 5 is a graphical representation showing T cell recall responses to ovalbumin (OVA) immunization. Mice were immunised subcutaneously with OVA 100 days post-BMT and recall responses of splenic T cells measured 14 days later. T cell proliferation in the presence of OVA was similar for age-matched control NOD mice (■) and recipients of T cell-depleted NOD (▼) or NOD-PI (▲) BM. Open symbols indicate proliferation in the absence of OVA. Data are from individual mice pooled from three separate experiments in which NOD and NOD-PI BMT were performed in parallel.

Figure 6 is a graphical representation of BM cultured in GM-CSF/IL-4 or GM-CSF/TGF- $\beta$ 1, cells harvested at day 5 and cell surface markers analysed by flow cytometry. Numbers denote the percentage of cells falling in that quadrant (A). GM-CSF/IL-4 or GM-CSF/TGF- $\beta$ 1 cultured BM was harvested at day 5 and endocytic activity measured by uptake of FITC-dextran. Plots show FITC-dextran uptake vs CD86 expression for CD11c-gated cells from GM-CSF/IL-4 cultured BM or FITC-dextran uptake vs CD11c expression for bulk GM-CSF/TGF- $\beta$ 1 cultured BM (B). BM was cultured in GM-CSF/TGF- $\beta$ 1 and cells harvested at day 5. Cell surface markers expressed on Gr-1<sup>+</sup> and CD11c<sup>+</sup> cells were analysed using 4-colour flow cytometry. Upper left dot plot shows gating used for analysis

of Gr-1<sup>+</sup>-gated and CD11c<sup>+</sup>-gated cells. Histogram overlays show Gr-1<sup>-</sup> gated (shaded) and CD11c-gated (open) cells (C). iDC from G+T BM expressed low levels of MHC class II and co-stimulation molecules and were weak stimulators in the mixed lymphocyte reaction (MLR).

5

**Figure 7** is a graphical representation showing that G+T BM from NOD-PI, but not control NOD mice, significantly inhibited ( $p < 0.01$ ) diabetes development when transferred i.v. to 4 week-old female NOD mice.

10 **Figure 8** is a series of flow cytometric dot blots revealing that G+T BM contained large numbers of undifferentiated CD11c<sup>-</sup>/CD11b<sup>+</sup>/Gr-1<sup>+</sup> myeloid cells, in addition to CD11c<sup>+</sup>/CD11b<sup>+</sup>/Gr-1<sup>-</sup> iDC.

**Figure 9** is a graphical representation showing proinsulin-encoding Gr-1<sup>+</sup> cells inhibits  
15 diabetes treated at four weeks.

**Figure 10** is a graphical representation showing proinsulin-encoding Gr-1<sup>+</sup> cells inhibits diabetes treated at four weeks ( $1.8 \times 10^6$  CD11c-depleted i.v.).

20 **Figure 11** is a photographic representation of Gr-1<sup>+</sup> myeloid cells differentiate to CD11c<sup>+</sup>/MHC class II<sup>+</sup> DC in vivo. Gr-1<sup>+</sup> cells were purified from GM-CSF/TGF- $\beta$ 1-cultured proinsulin-NOD BM by depletion of CD11c<sup>+</sup> cells, CFSE-labelled and injected directly into the spleen. Frozen sections of spleen were stained for immunofluorescence analysis. Localisation of CFSE- and antibody-labelled cells was performed by  
25 immunofluorescence microscopy. Panels show CFSE labelled cells (left), cells visualised with texas red conjugated mAb (centre) and merged images (right).

- 10 -

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a safe and effective protocol for treating and/or preventing autoimmune disease conditions.

5

The protocol generally involves the steps of:-

- (i) collecting a sample of HSCs and/or HPCs from an subject;
- 10 (ii) genetically modifying all or some of the HSCs and/or HPCs so that the HSCs and/or HPCs produce one or more autoantigens associated with the autoimmune disease; and
- (iii) introducing the genetically modified HSCs and/or HPCs into the same subject or a  
15 compatible subject and which then eventually become APCs expressing the autoantigen.

The above steps may be combined and/or the order changed. Additional steps may also be included.

20

Reference to a "subject" such as a human subject as well as an animal or avian subject. The terms "individual" and "subject" in relation to the animal being treated may be used interchangeably. An "animal" includes a human, primate, livestock animal (e.g. sheep, horse, cow, horse, donkey, goat, pig), laboratory test animal (e.g. rabbit, mouse, rat, guinea  
25 pig), companion animal (e.g. dog, cat) or captured wild animal. An "avian species" includes caged or aviary birds, poultry birds (e.g. chickens, bantams, geese, turkeys) and game birds.

The most preferred animal in terms of medical science is a human. The present invention  
30 extends, however, to veterinary uses of the protocol to reduce autoimmune disease conditions in non-human animals.

- 11 -

The HSCs and/or HPCs are generally obtained from a sample of bone marrow such as from drilling into the hip bone. However, the present invention further extends to isolating and where necessary sorting HSCs and HPCs from peripheral blood including cord blood  
5 and blood from the liver. The cells are generally introduced into the recipient *via*, for example, i.v. injection or infusion into the peripheral blood system or liver *via* the portal vein. However, direct introduction into a recipient's bone marrow, although not preferred, is nevertheless contemplated by the present invention.

10 The process of the present invention may be "syngeneic", "allogeneic" or "xenogeneic" with respect to the subjects within an animal species from which HSCs and/or HPCs are isolated and the subjects who receive the cells. A "syngeneic" process means that the subject from which the HSCs and/or HPCs are derived has the same MHC genotype as the recipient of the genetically modified HSCs and/or HPCs. An "allogeneic" process is  
15 where the HSCs and/or HPCs are from a MHC-incompatible subject to the subject to which the HSCs and/or HPCs are to be introduced. A "xenogeneic" process is where the HSCs and/or HPCs are from a different species to that to which the HSCs and/or HPCs are introduced. Preferably, the method of the present invention is conducted as a syngeneic process. To the extent that either an allogeneic or xenogeneic process is utilized, it should  
20 be understood that it may be necessary to modify the protocol such that any immunological responses, which may occur due to the mixing of foreign immuno-competent cells, are minimised.

Accordingly, the present invention contemplates a method for preventing or otherwise  
25 minimizing the risk of development of or reducing the severity of an autoimmune condition in a subject, said method comprising introducing into said subject, HSCs and/or HPCs which have been genetically modified such that they now produce one or more autoantigens associated with the autoimmune condition.

30 More particularly, the present invention provides a method for generating an antigen presenting cell (APC) which presents an autoantigen associated with an autoimmune

- 12 -

disease, the method comprising collecting a sample of hemopoetic stem cells (HSCs) and/or hemopoetic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding the autoantigen under conditions wherein the genetic material is expressed so that the HSCs and/or HPCs produce the autoantigens.

5

The HSCs and/or HPCs are developed into APCs expressing particular autoantigens. Examples of APCs include but are not limited to dendritic cells, B-lymphocytes, epithelial cells or macrophages.

- 10 As indicated above, the subject includes a human, non-human animal and avian subject. Preferably, the subject is a human. The subject (e.g. human) may have pre-clinical diabetes or may be at risk of developing diabetes or may have clinical diabetes.

- Also as indicated above, the method may involve the syngeneic, allogeneic or xenogeneic  
15 administration of HSCs and/or HPCs to a subject. However, a syngeneic protocol is preferred.

- Accordingly, in a preferred embodiment, the present invention provides a method for preventing or otherwise minimizing the risk of developing or reducing the severity of an  
20 autoimmune disease in a subject, said method comprising introducing into said subject syngeneic HSCs and/or HPCs which have been genetically modified to produce one or more autoantigens associated with the autoimmune condition.

- The preferred autoimmune disease is autoimmune diabetes, also known as type 1 diabetes  
25 or insulin-dependent diabetes. However, the present invention extends to the use of the subject protocol in the treatment of a range of autoimmune conditions. The only criterion is that an autoantigen associated with the disease condition be known. Examples of autoimmune conditions contemplated herein include *inter alia* systemic lupus, Crohn's disease, cardiomyopathy, hemolytic anemia, fibromyalgia, Graves' disease, ulcerative  
30 colitis, vasculitis, multiple sclerosis, myasthenia gravis, myositis, neutropenia, psoriasis, chronic fatigue syndrome, juvenile arthritis, juvenile diabetes, scleroderma, psoriatic

- 13 -

arthritis, Sjogren's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, idiopathic thrombocytopenic purpura (ITP), Hashimoto's disease, mixed connective tissue disease, interstitial cystitis, pernicious anemia, leukoencephalitis, alopecia areata, ankylosing spondylitis, primary biliary cirrhosis, anti-GBM nephritis, anti-TBM nephritis, 5 anti-phospholipid syndrome, polymyalgia rheumatica, polymyositis, autoimmune Addison's disease, chronic active hepatitis, vitiligo, autoimmune hyperlipidemia, autoimmune myocarditis, temporal arteritis, autoimmune thyroid disease, axonal and neuronal neuropathies, Behçet's disease, bullous pemphigoid, allergic asthma, osteoarthritis, Chagas' disease, uveitis, chronic inflammatory demyelinating 10 polyneuropathy (CIDP), cicatricial pemphigoid/benign mucosal pemphigoid, Cogan's syndrome, congenital heart block, Coxsackie myocarditis, demyelinating neuropathies, dermatomyositis, discoid lupus, phacoantigenic uveitis, polyarteritis nodosa, Dressler's syndrome, essential mixed cryoglobulinemia, Evan's syndrome, Goodpasture's syndrome, allergic rhinitis, Guillain-Barré syndrome, hypogammaglobulinemia, inclusion body 15 myositis, vesiculobullous dermatosis, Wegener's granulomatosis, Ménière's disease, Lambert-Eaton syndrome, Mooren's ulcer, non-typical celiac disease, ocular cicatricial pemphigoid, pemphigus vulgaris, perivenous encephalomyelitis, post-pericardiotomy syndrome, scleritis, sperm and testicular autoimmunity, Stiff man's syndrome, subacute bacterial endocarditis (SBE), sympathetic ophthalmia, transverse myelitis and necrotizing 20 myelopathy, type 1 autoimmune polyglandular syndrome, type II autoimmune polyglandular syndrome, pernicious anaemia and endometriosis.

According to a preferred embodiment, the present invention contemplates a method of preventing, minimizing the risk of development of or the severity of autoimmune diabetes 25 in a human subject, said method comprising administering to said human subject an effective amount of HSCs and/or HPCs isolated from said human subject or from a syngeneic subject and which HSCs and/or HPCs have been genetically modified such that they express an autoantigen associated with autoimmune diabetes.

30 The preferred autoantigen is proinsulin or an immunogenic homolog or antigen derivative, part, fragment or portion thereof. The proinsulin is generally of human origin although

- 14 -

humanized proinsulin molecules from, for example, pigs, sheep, horses, goats, mice or rats are also contemplated.

According to a most preferred embodiment, the present invention provides a method of preventing, minimizing the risk of development of or the severity of autoimmune diabetes in a human subject, said method comprising administering to said human subject an effective amount of HSCs and/or HPCs isolated from said human subject or from a syngeneic subject and which HSCs and/or HPCs have been genetically modified such that they produce proinsulin.

10

It is proposed herein that syngeneic transplantation of gene-modified HSC and/or HPCs is a novel approach to antigen-specific immunotherapy which advances the principle of regulating autoimmune disease from within the hematopoietic compartment.

15 Preferably, the autoimmune disease is diabetes and the autoantigen is proinsulin since proinsulin contains T cell epitopes implicated in human (Rudy *et al.*, *Mol. Med.* 1: 625-633, 1995) and mouse (Chen *et al.*, *J. Immunol.* 167: 4926-4935, 2001) type 1 diabetes. In work leading up to the present invention, the inventors observed that NOD mice transgenically- expressing proinsulin targeted to APCs by an MHC class II promoter  
20 (French *et al.*, 1997, *supra*) contained bone marrow which could be used to adoptively transfer protection against the development of autoimmune diabetes following bone marrow transplantation to a wild-type NOD mouse. Protection from diabetes was profound in recipients of bone marrow from NOD-PI mice. By transferring highly purified HSC or HPCs, protection can be attributed to the APC progeny of engrafted HSCs/HPCs  
25 rather than other potentially immunoregulatory cells transferred in whole or T cell-depleted bone marrow. Most importantly, transfer of small numbers of genetically-modified HSCs totally prevents diabetes. HSC transplantation also demonstrates that diabetes transferred by wild-type NOD HSC is due to generation of diabetogenic T cells *de novo* rather than to transfer of diabetogenic T cells. Nevertheless, diabetogenic T cells clearly either do not  
30 develop or fail to acquire effector function in mice destined to express proinsulin in APC.

- 15 -

These results provide proof of principle for genetically-modified HSCs as a therapeutic tool for autoimmune disease prevention.

The context in which antigen presentation occurs controls the balance of T cell immunity  
5 (Garza *et al.*, *J. Exp. Med.* 191: 2021-2027, 2000; Frazer *et al.*, *J. Immunool* 167:6180-6187, 2001). Antigen presented by resting APC induces inactivation of T cells (Niimi *et al.*, 1998, *supra*; Finkelman *et al.*, 1996, *supra*; Hawiger *et al.*, 2001, *supra*) and inhibits antigen-specific Ab production (Finkelman *et al.*, 1996, *supra*). By transgenically targeting antigen expression, dendritic cells (DC) have been shown to play a key role in  
10 thymic deletion of antigen-specific T cells (Brockner *et al.*, *J. Exp. Med.* 185: 541-550, 1997). Importantly, suppression of T cell responses in the periphery has also been described following administration of DC-targeted antigen (Finkelman *et al.*, 1996, *supra*; Hawiger *et al.*, 2001, *supra*). The ability to harness peripheral mechanisms of immune tolerance is likely to be the key to autoantigen-specific immunotherapy in subjects with  
15 autoreactive T cells.

While the inventors used myeloablative conditioning with irradiation to favour maximum engraftment of donor HSCs, this would not be acceptable in asymptomatic humans with pre-clinical autoimmune diabetes. However, as no MHC barrier exists, the approach is  
20 adaptable to protocols which require no toxic pre-bone marrow transplantation conditioning. By using HSCs derived from transgenic mice, the need to genetically-engineer HSCs *ex vivo*, which has been a major hurdle for HSC therapy, is by-passed. For human application, vectors capable of effectively transducing HSCs for long-term gene expression after engraftment are required. Gene expression can be effectively targeted to  
25 MHC class II<sup>+</sup> APC *in vivo* by lentiviral-vector transduction of human HSC (Cui *et al.*, *Blood* 99: 399-408, 2002). Therefore, a strategy whereby HSCs and/or HPCs are harvested from peripheral blood, optionally following cytokine-induced mobilization, genetically modified and reinfused is the preferred approach to the therapy of autoimmune disease.

30

Accordingly, another aspect of the present invention contemplates a method for treating or



- 16 -

reducing the risk of development of or reducing the severity of diabetes in a human, said method comprising:-

- 5 (i) isolating HSCs and/or HPCs from peripheral blood or bone marrow, optionally including the steps of cytokine-mediated mobilization of the HSCs and/or HPCs;
- (ii) genetically modifying the HSCs and/or HPCs so that the cells now produce proinsulin or an immunogenic homolog, antigenic derivative, part, fragment or portion thereof and continue to do so as APCs; and
- 10 (iii) infusing or introducing the genetically modified cells into a human subject.

Reference to genetically modifying HSCs and/or HPCs includes introducing nucleic acid molecules encoding proinsulin or other autoantigens into the genome of the cells.

15 Generally, the nucleic acid molecule is DNA. The DNA may encode a full length autoantigen, multiple full length autoantigens or one or more fragments of one or more autoantigens which carry antigenic epitopes.

Yet another aspect of the present invention provides a vector useful for introducing genetic

20 material encoding an autoantigen such as proinsulin, said vector comprising a nucleotide sequence encoding the autoantigen or an antigenic fragment thereof and a selectable marker.

A selectable marker in the vector allows for selection of targeted cells that have stably

25 incorporated the autoantigen-encoding DNA. This is especially useful when employing relatively low efficiency transformation techniques such as electroporation, calcium phosphate precipitation and liposome fusion where typically fewer than 1 in 1000 cells will have stably incorporated the exogenous DNA. Using high efficiency methods, such as viral vectors and microinjection into nuclei, typically from 5-25% of the cells will have

30 incorporated the DNA; and it is, therefore, feasible to screen the targeted cells directly

- 17 -

without the necessity of first selecting for stable integration of a selectable marker. Either isogenic or non-isogenic DNA may be employed.

Examples of selectable markers include genes conferring resistance to compounds such as antibiotics, genes conferring the ability to grow on selected substrates, genes encoding proteins that produce detectable signals such as luminescence. A wide variety of such markers are known and available, including, for example, antibiotic resistance genes such as the neomycin resistance gene (*neo*) and the hygromycin resistance gene (*hyg*). Selectable markers also include genes conferring the ability to grow on certain media substrates such as the *tk* gene (thymidine kinase) or the *hprt* gene (hypoxanthine phosphoribosyltransferase) which confer the ability to grow on HAT medium (hypoxanthine, aminopterin and thymidine); and the bacterial *gpt* gene (guanine/xanthine phosphoribosyltransferase) which allows growth on MAX medium (mycophenolic acid, adenine and xanthine). Other selectable markers for use in mammalian cells and plasmids carrying a variety of selectable markers are described in Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbour, New York, USA, 1990.

The selectable marker may depend on its own promoter for expression and the marker gene may be derived from a very different organism than the organism being targeted (e.g. prokaryotic marker genes used in targeting mammalian cells). However, it is preferable to replace the original promoter with transcriptional machinery known to function in the recipient cells. A large number of transcriptional initiation regions are available for such purposes including, for example, metallothionein promoters, thymidine kinase promoters,  $\beta$ -actin promoters, immunoglobulin promoters, SV40 promoters and human cytomegalovirus promoters. A widely used example is the pSV2-*neo* plasmid which has the bacterial neomycin phosphotransferase gene under control of the SV40 early promoter and confers in mammalian cells resistance to G418 (an antibiotic related to neomycin). A number of other variations may be employed to enhance expression of the selectable markers in animal cells, such as the addition of a poly(A) sequence and the addition of synthetic translation initiation sequences. Both constitutive and inducible promoters may be used.

- 18 -

The DNA is preferably modified by homologous recombination. The target DNA can be in any organelle of the HSC or HPC including the nucleus and mitochondria and can be an intact gene, an exon or intron, a regulatory sequence or any region between genes.

5

Homologous DNA is a DNA sequence that is at least 70% identical with a reference DNA sequence. An indication that two sequences are homologous is that they will hybridize with each other under stringent conditions (Sambrook *et al.*, 1990, *supra*).

- 10 The present invention also provides a kit in multiple compartmental form, the kit comprising a first compartment adapted to receive a source of HSCs and/or HPCs from a subject; a second compartment adapted to contain genetic material encoding an autoantigen; optionally a third or more compartments adapted to contain reagents wherein the kit comprises instructions for use comprising in a method comprising collecting a
- 15 sample of hemopoietic stem cells (HSCs) and/or hemopoietic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding the autoantigen under conditions wherein the genetic material is expressed so that the HSCs and/or HPCs produce the autoantigens.
- 20 In a related aspect, the present invention further provides a pharmaceutical kit comprising reagents and/or compartments adapted for use in isolation of HSCs and/or HPCs from peripheral blood or bone marrow, their genetic manipulation to express DNA encoding proinsulin or an antigenic part thereof or another autoantigen associated with autoimmune diabetes and/or means to reintroduce the genetically modified cells to a subject, either to
- 25 the peripheral blood system or to bone marrow.

The present invention is further described by the following non-limiting Examples.

## EXAMPLE 1

### *General methods*

#### *Mice*

5

NOD (non-obese diabetic) and NOD.scid mice were bred under specific-pathogen free conditions. NOD mice transgenic for mouse proinsulin II (NOD-PI) under control of the MHC class II (I-E $\alpha$ ) promoter (French *et al.*, *Diabetes* 46: 34-39, 1997) were used after breeding to homozygosity. As the incidence of spontaneous diabetes is highest in wild-type NOD females, only females were used as recipients and bone marrow (BM) donors.

#### *Antibodies and flow cytometry*

Flow cytometric analysis was performed as described (Steptoe *et al.*, *J. Immunol.* 168: 5032-5041, 2002). The following mAbs were purified from tissue culture supernatants and then used in conjugation reactions: Antibodies directed against Gr-1 (Ly-6G; RB6-8C5), F4/80 (F4/80), CD11b (5C6 or M1/70), CD11c (N418), MHC class II (10.2.16 [I-A<sup>k,g7,r,f,s</sup>]), MHC class I (M1/42), M-CSF R (AFS-98), CD40 (FGK-45), B220 (RA3-6B2) and CD86 (GL-1) Streptavidin (SA)-fluorochrome conjugates (SA-FITC, SA-phycoerythrin, SA- allophycocyanin, SA-texas red), mAb to CD4 (CT-CD4), CD8 $\alpha$  (CT-CD8a) and FITC, PE and Tricolor streptavidin conjugates were from Caltag (Burlingame, CA). Monoclonal antibodies directed to anti-CD3 (145-2C11), SCA-1 (E13-161.7), CD40 (3/23), MAC-3 (M3/84), CD13 (R3-242), CD62-L (MEL-14), CD31 (MEC13.3), CD43 (S7), CD11a (2D7), CD49d (R1-2) were purchased from PharMingen (San Diego, CA). In addition, anti-mouse FIRE, anti-CD3 (KT3), c-kit (ACK-2) was used.

For analysis of PBL mice were bled by retro-orbital venous sinus puncture with a fine glass capillary tube. Blood was collected in Alsever's anticoagulant, erythrocytes lysed and leukocytes stained and analyzed by flow cytometry. Leukocyte number determined with a hemocytometer was calibrated according to blood volume obtained. To control for inter-experimental variation, three age-matched female NOD were included in each

- 20 -

analysis. Spleens were pressed through stainless steel mesh and cells suspended in RPMI containing 10% v/v FCS.

### *BM preparation and transfer*

5

Mice (8-12 weeks old) were euthanased and femurs and tibiae collected into cold mouse-toxicity phosphate buffered saline (PBS). BM was flushed with ice cold PBS containing 2.5% v/v FCS (F2.5) (Trace Scientific, Melbourne Australia) and erythrocytes removed by  $\text{NH}_4\text{Cl}$ /TRIS buffer lysis. BM was washed in F2.5 and collected by centrifugation. For T cell depletion, BM was resuspended in F2.5, incubated with anti-CD3 mAb (KT3, 5  $\mu\text{g/ml}$ ) for 30 minutes at  $4^\circ\text{C}$ , then washed in F2.5. Antibody-labeled cells were depleted with anti-rat IgG immunomagnetic beads (Dynabeads, Dynal Biotech, Carlton South, Victoria, Australia). For sorted HSC or HPC, lineage marker-positive cells were depleted by immunomagnetic beads with a mix of FITC-conjugated lineage-specific mAb (KT3, 15 M1/70, RA3.6B2, RB6-8C5, TER-119) at predetermined optimal concentrations. Remaining cells were labelled with anti-c-kit-phycoerythrin. For HSC isolation, lineage-depleted cells were also co-stained with anti-SCA-1-biotin, washed and stained with streptavidin-Tricolor.  $\text{Lin}^-/\text{c-kit}^+/\text{SCA-1}^+$  (HSC) or  $\text{lin}^-/\text{c-kit}^+$  (HPC) cells were collected by sterile sorting (FACSS, Becton Dickinson, San Diego, CA). Irradiated mice received a total of 950 cGy (Theratron  $^{60}\text{Co}$ , Theratronics, Kanata, ON, Canada) as two equal doses 2-3 hours apart. Cells ( $10^7$  BM or T cell-depleted BM, unless stated otherwise) were suspended in PBS and injected i.p. in 250  $\mu\text{l}$  or i.v. in 100  $\mu\text{l}$  for HSC ( $10^3$ ) and HPC ( $2.5 \times 10^4$ ), 1-3 hours after irradiation in the case of irradiated mice. Irradiated mice were maintained on neomycin-supplemented drinking water for 3 weeks post-BMT. Any mice 25 showing signs of physical distress in the immediate post-BMT period were euthanased and excluded from analysis.

### *T cell recall response*

30 Mice were immunized s.c. in the flank with 100  $\mu\text{g}$  ovalbumin (OVA) (Grade V, Sigma St Louis, MO) in Complete Freund's Adjuvant (Difco, Detroit, MI). Spleens collected 14

- 21 -

days later from euthanased mice were pressed through stainless steel mesh and cells suspended in RPMI medium (GIBCO, Rockville, MA) containing 10% v/v FCS (Trace Scientific, Melbourne Australia),  $10^{-3}$  M sodium pyruvate,  $10^{-4}$  M non-essential amino acids (GIBCO),  $2 \times 10^{-3}$  M glutamine,  $5 \times 10^{-5}$  M 2-mercaptoethanol (Sigma). Splenocytes  
5 were plated in triplicate ( $2.5 \times 10^5$  cells/well, 200  $\mu$ l, 96 well flat-bottom plates) in the absence or presence of OVA (100  $\mu$ g/ml). Cells were harvested on day 4 onto glass filter mats.  $^3$ H-thymidine (1  $\mu$ Ci/well) was added during the final 18 hours of culture. Incorporated radioactivity reflecting cell proliferation was measured in a scintillation counter (Topcount, Packard, Groningen, The Netherlands) and results expressed as mean  
10 stimulation index (SI)  $\pm$  standard deviation.

#### *Monitoring for diabetes*

Mice were urine tested for glucose weekly with Diastix test strips (Bayer, Pymble, NSW  
15 Australia). In glycosuric mice blood glucose was measured with a meter (Accu-Chek, Roche, Castle Hill, NSW, Australia). Mice were considered diabetic when two consecutive blood glucose readings were  $>12.0$  mM. Mice were euthanased when diabetic or showing sign of physical distress.

#### *20 Assessment of insulinitis and sialitis*

Pancreata were removed from euthanased mice and placed in Bouin's fixative for 24 h and then transferred to 70% v/v ethanol. Fixed tissues were embedded in paraffin and H&E stained sections separated by 250-300  $\mu$ m were prepared. Insulitis was scored in a masked  
25 fashion as described (Leiter, *Proc. Natl. Acad. Sci. USA* 79: 630-634, 1982). Sublingual glands were removed and prepared as for pancreata. The number of inflammatory foci present were counted and expressed as a mean per section.

- 22 -

*Statistical analysis*

Comparison of Kaplan-Meier survival curves was performed using the log-rank test (GraphPad Prism, GraphPad Software Inc., San Diego, CA). Insulinitis scores between  
5 BMT groups were compared by Student-*t*-test.

**EXAMPLE 2***Transplantation of NOD-PI bone marrow prevents diabetes*

10 Whole BM from NOD or NOD-PI mice was transplanted to 4 week-old irradiated female NOD recipients. While the onset was delayed slightly, the overall incidence of diabetes in NOD BM recipients (7/12) was similar to untreated controls (15/23) (Figure 1A). In contrast, diabetes was almost completely prevented in recipients of NOD-PI BM (1/16,  $P=0.0032$ ) (Figure 1A). NOD mice have an inherently high risk of thymoma development  
15 that is exacerbated by impaired immune surveillance or exposure to ionising radiation (Prochazka *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 3290-3294, 1992; Shultz *et al.*, *J. Immunol.* 164: 2496-2507, 2000). Exclusion of mice diagnosed with thymomas at necropsy increased the proportion of mice with diabetes in both groups (NOD 7/10, NOD-PI 1/5) but the difference in diabetes incidence remained significant between groups  
20 ( $P=0.041$ ). Because of their longer diabetes-free survival time, recipients of NOD-PI BM had a higher proportion of thymomas (11/16) compared to NOD BM recipients (2/12).

**EXAMPLE 3***T cell-depletion does not modify the protective effect of transplanted NOD-PI BM*

25

Separate studies had found that mature T cells in NOD BM were capable of transferring diabetes to immune-deficient NOD.scid mice. Diabetes development, following transfer of whole BM, might, therefore, have reflected the diabetogenic potential of transferred mature T cells. However, it was found that, whereas whole NOD BM transferred diabetes  
30 to at least 50% of non-irradiated T cell-deficient NOD.scid mice, no mice that received BM from NOD-PI mice developed diabetes.

- 23 -

- As mature T cells in NOD, but not NOD-PI, BM could transfer diabetes, the effect of transplanting T cell-depleted BM to irradiated 4 week-old mice was tested. Recipients of T cell depleted NOD BM developed diabetes at a rate and incidence (10/15) similar to untreated controls (7/12) (Figure 1B). In contrast, diabetes development was significantly less (3/17,  $P=0.003$ ) in recipients of T cell-depleted NOD-PI BM (Figure 1B). When mice with thymomas apparent at necropsy were removed from the analysis the difference between groups remained statistically significant ( $P=0.012$ ).
- Cellular immune infiltration of pancreatic islets (insulitis) was assessed 100 days post-BMT ( $1 \times 10^7$  T cell-depleted BM) In recipients of NOD-PI T cell-depleted BM, 54% of islets were free of insulitis (Figure 2A) and mononuclear cell infiltration was restricted to the islet periphery (peri-insulitis). In contrast, in recipients of NOD T cell-depleted BM only 28% of islets were free of insulitis and there was extensive infiltration into the islets (Figure 2B). These observations were reflected by a significantly reduced mean insulitis score for NOD-PI compared to NOD recipients ( $P=0.008$ ) (Figure 2C). Similar results were observed after transplantation of  $5 \times 10^6$  T cell-depleted BM. In contrast to insulitis, mononuclear cell infiltration of the sublingual gland (sialitis) was similar in recipients of either NOD-PI or NOD T cell-depleted BM and age-matched unmanipulated controls (Figure 2D). This indicates that NOD-PI BM transfer protects specifically against islet auto-immunity.

#### EXAMPLE 4

##### *PI-encoding hematopoietic stem and progenitor cells transfer diabetes prevention*

- Hematopoietic stem cells ( $\text{lin}^-/\text{c-kit}^+/\text{SCA-1}^+$ ) or progenitor cells (HPC) ( $\text{lin}^-/\text{c-kit}^+$ ) were sterile-purified from NOD and NOD-PI BM. To determine their effect on the development of diabetes, small numbers of either HSC or HPC were transplanted into irradiated 4 week-old recipients. Hematopoietic reconstitution was rapid and PBL populations were restored by 8 weeks post-BMT. Diabetes was totally prevented in recipients of NOD-PI HSC and its incidence significantly reduced in recipients of NOD-PI HPC (Figure 3).



- 24 -

## EXAMPLE 5

### *Diabetes prevention by NOD-PI BM is not due to impaired immune reconstitution*

5 To exclude the possibility that the protective effect of NOD-PI BMT was the result of impaired immune reconstitution, peripheral blood leucocyte (PBL) populations were first analysed. Ten to fourteen days post-T cell-depleted BMT, circulating leucocytes were substantially reduced in number in both NOD and NOD-PI recipients (Figure 4A). The proportions of T lymphocytes ( $CD4^+$ ,  $CD8^+$ ) and B lymphocytes ( $B220^+$ ) were reduced  
10 (50-75%, 25% and 80-85%, respectively) relative to age-matched controls, whereas the proportion of myeloid ( $CD11b^+$ ) cells was increased ~2.5-fold. At 8 and 16 weeks post-BMT, total PBL count (Figure 4A) and the relative proportion of PBL subsets (Figure 4B) were normal, indicating similar reconstitution between groups. The ability of BMT recipients to mount a T cell-mediated immune response was then investigated. Normal  
15 age-matched NOD mice and recipients of NOD or NOD-PI T cell-depleted BM were immunized with ovalbumin (OVA) 100 days post-BMT. Two weeks later, *in vitro* recall responses to OVA were similar in untreated mice and either BMT group (Figure 5). Thus, NOD-PI BMT was not associated with evidence of impaired immune reconstitution.

## EXAMPLE 6

### *Cytokine-stimulated myeloid cells comprise undifferentiated DC precursors*

As a source of 'immature' DC (iDC), BM was cultured in GM-CSF and TGF-beta (G+T). These cultures contained mixtures of cell types, dominated by small round cells with  
25 annular or segmented nuclei that expressed the myeloid differentiation marker Gr-1, features characteristic with undifferentiated myeloid precursors. A small proportion of the cells had a monocyte-like or immature DC-like appearance and expressed low levels of MHC class II restricted primarily to intracellular granules. To further define these subpopulations of cells, BM cultured in comparisons were made between GM-CSF/TGF-  
30  $\beta 1$  and GM-CSF/IL-4, as the latter contains a mix of phenotypically mature and immature DC along with small numbers of undifferentiated myeloid cells. In contrast to BM cells

- 25 -

cultured in GM-CSF/IL-4, BM cultured in GM-CSF/TGF- $\beta$ 1 contained only a low frequency of cells expressing the DC-specific marker CD11c (see Figure 6A), the remainder comprising almost entirely Gr-1<sup>+</sup> cells. Levels of antigen-presenting (MHC class II) and co-stimulation molecules (CD86 and CD40) expressed on CD11c<sup>+</sup> DC in  
5 GM-CSF/TGF- $\beta$ 1-cultured BM were low and similar to those of phenotypically immature DC generated in GM-CSF/IL-4 (see Figure 6A). Endocytic activity, a hallmark of functionally-immature (CD11c<sup>+</sup>/CD86<sup>lo</sup>) DC, were measured by FITC dextran uptake. In GM-CSF/IL-4 supplemented cultures, only CD11c<sup>+</sup>/CD86<sup>lo</sup> immature DC were endocytically active; in GM-CSF/TGF- $\beta$ 1-supplemented cultures, only CD11c<sup>+</sup> cells were endocytically  
10 active.

iDC from G+T BM expressed low levels of MHC class II and co-stimulation molecules (Figure 6) and were weak stimulators in the mixed lymphocyte reaction. G+T BM from NOD-PI, but not control NOD mice, significantly inhibited ( $p < 0.01$ ) diabetes development  
15 when transferred i.v. to 4 week-old female NOD mice (Figure 7). Further investigation revealed that G+T BM contained large numbers of undifferentiated CD11c<sup>-</sup>/CD11b<sup>+</sup>/Gr-1<sup>+</sup> myeloid cells in addition to CD11c<sup>+</sup>/CD11b<sup>+</sup>/Gr-1<sup>-</sup> iDC (Figure 8).

## EXAMPLE 7

20

### *Precursor DC*

Depletion of Gr-1<sup>+</sup> cells reduced the ability of G+T BM to inhibit diabetes, whereas depletion of CD11c<sup>+</sup> iDC did not (Figure 9). Transfer of purified Gr-1<sup>+</sup> myeloid cells from NOD-PI ( $p < 0.01$ ) but not control NOD mice inhibited diabetes development in recipient  
25 mice, confirming the protective role of these cells (Figure 10).

Unlike iDC, CD11c<sup>-</sup>/CD11b<sup>+</sup>/Gr-1<sup>+</sup> myeloid cells did not rapidly acquire a mature CD11c<sup>+</sup>/CD86<sup>hi</sup> phenotype in response to activational stimuli (LPS, anti-CD40). Instead, they gradually acquired mature DC characteristics over 5-7 days in culture in GM-CSF/IL-  
30 4/TNF- $\alpha$ . CD11c<sup>-</sup>/CD11b<sup>+</sup>/Gr-1<sup>+</sup> cells present in G+T BM cultures therefore represent DC precursors. Hence, the foregoing data indicate that myeloid DC precursors encoding a

- 26 -

disease-specific autoantigen (proinsulin) are able to prevent autoimmune disease.

## EXAMPLE 8

### *Myeloid cells differentiate to CD11c+/MHC class II+ DC in vivo*

5

To determine the *in vivo* differentiation and survival of transferred cells, Gr1<sup>+</sup> cells were purified from GM-CSF/TGF- $\beta$ 1-cultured proinsulin-NOD BM by depletion of CD11c<sup>+</sup> cells. The cells were then CFSE labelled and injected directly into spleen. Frozen sections of spleen were stained for Immunofluorescence analysis. Localization of CFSE-and antibody labelled cells (either MHC class II, CD11c, CD11b or GR-1) was performed using Immunofluorescence microscopy. Figure 11 demonstrates the identification of cell s which stain positive for CFSE and all four markers tested. The left panels show CFSE labelled cells, the middle panels shows cells visualized with texas red conjugated mAB, and the right panel shows merged images. Dual staining is indicated by the presence of bright white spots in the right panel.

15

### *Immunohistology*

Cryostat sections (5um) were cut from frozen OCT-embedded (Tissue-Tek, Miles Inc. Elkhart, IN) tissues, air dried and fixed with cold 100% ethanol prior to immunostaining or mounting. Avidin/biotin binding sites were blocked using avidin/biotin blocking reagents (Vector, Burlingame, CA) and non-specific protein interactions blocked with 1% BSA. Biotinylated primary antibodies were applied at predetermined optimal concentrations for one hour at room temperature. After washing, streptavidin-HRP (Vector ABC-Elite, Vector, Burlingame, CA) or streptavidin-texas red was applied for a further hour. Immunoperoxidase slides were washed and staining developed with enzyme substrate (VectorRed, Vector, Burlingame, CA). Immunofluorescence slides were rinsed and mounted in anti-fade reagent (DAKO Corp., Carpinteria, CA).

25

- 27 -

*Cytospins*

Cytospins were prepared using a cytofuge (Shandon, Pittsburgh, PA). Cytospins were stained using Diff Quik (Lab Aids Pty Ltd, Narrabeen, NSW Australia) or by  
5 immunohistochemistry as described.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also  
10 includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

**BIBLIOGRAPHY**

- Brocker, T., Riedinger, M., Karjalainen, K. 1997. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. *J. Exp. Med.* 185: 541-550.
- 5 Burt, R.K., Slavin, S., Burns, W.H., Marmont, A.M. 2002. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? *Blood* 99: 768-784.
- 10 Castro-Malaspina, H., Harris, R.E., Gajewski, J., Ramsay, N., Collins, R., Dharan, B., King, R., Deeg, H.J. 2002. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. *Blood* 99: 1943-1951.
- 15 Chen, W., Bergerot, I., Elliott, J.F., Harrison, L.C., Abiru, N., Eisenbarth, G.S., Delovitch, T.L. 2001. Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. *J. Immunol.* 167: 4926-4935.
- 20 Cui, y., Golob, J., Kelleher, E., Ye, Z., Pardoll, D., Cheng, L. 2002. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced human hematopoietic stem/progenitor cells. *Blood* 99: 399-408.
- 25 El-Badri, N.S., Wang, B.Y., Steele, A., Cherry, Marikar, Y., Mizobe, K., Good, R.A. 2000. Successful prevention of autoimmune disease by transplantation of adequate number of fully allogeneic hematopoietic stem cells. *Transplantation* 70: 870-877.
- 30 Frazer, I.H., De Kluyver, R., Leggatt, G.R., Guo, H.Y., Dunn, L., White, O., Harris, C., Liem, A., Lambert, P. 2001. Tolerance or immunity to a tumor antigen expressed in

somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. *J. Immunol.* 167: 6180-6187.

French, M.B., Allison, J., Cram, D.S., Thomas, H.E., Dempsey-Collier, M., Silva,  
5 A., Georgiou, H.M., Kay, T.W., Harrison, L.C., Lew, A.M. 1997. Transgenic expression of  
mouse proinsulin II prevents diabetes in non-obese diabetic mice. *Diabetes*. 46: 34-39.

Garza, K.M., Chan, S.M., Suri, R., Nguyen, L.T., Odermatt, B., Schoenberger, S.P.,  
Ohashi, P.S. 2000. Role of antigen-presenting cells in mediating tolerance and  
10 autoimmunity. *J. Exp. Med.* 191: 2021-2027.

Himeno, K., Good, R.A. 1988. Marrow transplantation from tolerant donors to treat and  
prevent autoimmune diseases in BXSB mice. *Proc. Natl. Acad. Sci. U.S.A.* 85: 2235-2239.

15 Ikehara, S., Ohtsuki, H., Good, R.A., Asamoto, H., Nakamura, T., Sekita, K., Muso, E.,  
Tochino, Y., Ida, T., Kuzuya, H. *et al.* 1985. Prevention of type 1 diabetes in non-obese  
diabetic mice by allogeneic bone marrow transplantation. *Proc. Natl. Acad. Sci. U.S.A.* 82:  
7743-7747.

20 Kaufman, C.L., Li, H., Ildstad, S.T. 1997. Patterns of hemopoietic reconstitution in non-  
obese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of  
disease-resistant marrow. *J. Immunol.* 158: 2435-2442.

Kirzner, R.P., Engelman, R.W., Mizutani, H., Specter, S., Good, R.A. 2000. Prevention of  
25 coronary vascular disease by transplantation of T cell-depleted bone marrow and  
hematopoietic stem cell preparation in autoimmune-prone w/BF(1) mice. *Biol. Blood  
Marrow Transplant.* 6: 513-522.

LaFace, D.M., Peck, A.B. 1989. Reciprocal allogeneic bone marrow transplantation  
30 between NOD mice and diabetes-non-susceptible mice associated with transfer and  
prevention of autoimmune diabetes. *Diabetes*. 38: 894-901.

- Leiter, E.H. 1982. Multiple low-dose streptozotocin-induced hyperglycemia and insulinitis in C57BL mice: influence of inbred background, sex and thymus. *Proc. Natl. Acad. Sci. U.S.A.* 79: 630-634.
- 5 Li, H., Kaufman, C.L., Boggs, S.S., Johnson, P.C., Patrene, K.D., Ildstad, S.T. 1996. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulinitis in non-obese diabetic (NOD)mice. *J. Immunol.* 156: 380-388.
- 10 Prochazka, M., Gaskins, H.R., Shultz, L.D., Leiter, E.H. 1992. The non-obese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. *Proc. Natl. Acad. Sci. U.S.A.* 89: 3290-3294.
- 15 Ratanatharathorn, V., Ayash, L., Lazarus, H.M., Fu, J., Uberti, J.P. 2001. Chronic graft-versus-host disease: clinical manifestation and therapy. *Bone Marrow Transplant.* 28: 121-129.
- Rudy, G., Stone, N., Harrison, L.C., Colman, P.G., McNair, P., Brusic, V., French, M.B.,  
20 Honeyman, M.C., Tait, B., Lew, A.M. 1995. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. *Mol. Med.* 1: 625-633.
- Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor, New  
25 York, USA, 1990.
- Shultz, L.D., Lang, P.A., Christianson, S.W., Gott, B., Lyons, B., Umeda, S., Leiter, E., Hesselton, R., Wagar, E.J., Leif, J.H. *et al.* 2000. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid  
30 cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. *J. Immunol.* 164: 2496-2507.

- 31 -

Steptoe, R.J., Ritchie, J.M., Harrison, L.C. 2002. Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone non-obese diabetic mice. *J. Immunol.* 168: 5032-5041.



**CLAIMS**

1. A method for generating an antigen presenting cell (APC) which presents an autoantigen associated with an autoimmune disease, said method comprising collecting a sample of hemopoietic stem cells (HSCs) and/or hemopoietic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding said autoantigen under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said autoantigens.
2. The method of claim 1, wherein said APC is selected from the group consisting of a dendritic cell, B-lymphocyte, epithelial cell, monocyte and macrophage.
3. The method of claim 2, wherein said APC is a dendritic cell.
4. The method of claim 1, wherein said subject is selected from the group consisting of a human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig, dog, cat, bird, chicken, bantams, geese and turkeys.
5. The method of claim 1, wherein said subject is a human.
6. The method of claim 1, wherein said HSCs and/or HPCs are derived from a source selected from the group consisting of bone marrow from hipbone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.
7. The method of claim 6, wherein said HSCs and HPCs are derived from bone marrow from hipbone.
8. The method of claim 1, wherein said autoantigen is associated with a disease selected from the group consisting of type 1 diabetes or insulin-dependent diabetes, systemic lupus, Crohn's disease, cardiomyopathy, hemolytic anemia, fibromyalgia, Graves' disease, ulcerative colitis, vasculitis, multiple sclerosis, myasthenia gravis,

- 33 -

myositis, neutropenia, psoriasis, chronic fatigue syndrome, juvenile arthritis, juvenile diabetes, scleroderma, psoriatic arthritis, Sjogren's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, idiopathic thrombocytopenic purpura (ITP), Hashimoto's disease, mixed connective tissue disease, interstitial cystitis, pernicious anemia, leukoencephalitis, alopecia areata, ankylosing spondylitis, primary biliary cirrhosis, anti-GBM nephritis, anti-TBM nephritis, anti-phospholipid syndrome, polymyalgia rheumatica, polymyositis, autoimmune Addison's disease, chronic active hepatitis, vitiligo, autoimmune hyperlipidemia, autoimmune myocarditis, temporal arteritis, autoimmune thyroid disease, axonal and neuronal neuropathies, Behçet's disease, bullous pemphigoid, allergic asthma, osteoarthritis, Chagas' disease, uveitis, chronic inflammatory demyelinating polyneuropathy (CIP), cicatricial pemphigoid/benign mucosal pemphigoid, Cogan's syndrome, congenital heart block, Coxsackie myocarditis, demyelinating neuropathies, dermatomyositis, discoid lupus, phacoantigenic uveitis, polyarteritis nodosa, Dressler's syndrome, essential mixed cryoglobulinemia, Eyan's syndrome, Goodpasture's syndrome, allergic rhinitis, Guillain-Barré syndrome, hypogammaglobulinemia, inclusion body myositis, vesiculobullous dermatosis, Wegener's granulomatosis, Ménière's disease, Lambert-Eaton syndrome, Mooren's ulcer, non-typical celiac disease, ocular cicatricial pemphigoid, pemphigus vulgaris, perivenous encephalomyelitis, post-pericardiotomy syndrome, scleritis, sperm and testicular autoimmunity, Stiff man's syndrome, subacute bacterial endocarditis (SBE), sympathetic ophthalmia, transverse myelitis and necrotizing myelopathy, type 1 autoimmune polyglandular syndrome, type II autoimmune polyglandular syndrome, pernicious anaemia and endometriosis.

9. The method of claim 1, wherein said autoimmune disease is insulin dependent diabetes.

10. The method of claim 1, wherein said autoantigen is proinsulin or an immunogenic homolog, antigen derivative, part, fragment or portion thereof.

11. The method of claim 10, wherein said proinsulin is of human origin.

- 34 -

12. The method of claim 10, wherein said proinsulin is a humanized proinsulin, wherein said proinsulin is derived from the group selected from cow, pig, sheep, horse, goat, mouse and rat.
- 5 13. A method of preventing or treating an autoimmune disease in a subject comprising introducing into said subject an APC which presents an autoantigen associated with an autoimmune disease, said method comprising collecting a sample of hemopoietic stem cells (HSCs) and/or hemopoietic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding said autoantigen under conditions  
10 wherein said genetic material is expressed so that the HSCs and/or HPCs produce said autoantigens.
14. The method of claim 13, wherein said APC is selected from a dendritic cell, B-lymphocyte, epithelial cell, monocyte and macrophage.
- 15 15. The method of claim 14, wherein said APC is a dendritic cell.
16. The method of claim 13, wherein said subject is selected from the group consisting of a human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig,  
20 dog, cat, bird, chicken, bantams, geese and turkeys.
17. The method of claim 13, wherein said subject is a human.
18. The method of claim 13, wherein said cell is derived from bone marrow from the  
25 hip bone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.
19. The method of claim 18, wherein said cell is derived from bone marrow from a hip bone.
- 30 20. The method of claim 13, wherein said autoantigen is associated with a disease selected from the group consisting of type 1 diabetes or insulin-dependent diabetes,

- 35 -

- systemic lupus, Crohn's disease, cardiomyopathy, hemolytic anemia, fibromyalgia, Graves' disease, ulcerative colitis, vasculitis, multiple sclerosis, myasthenia gravis, myositis, neutropenia, psoriasis, chronic fatigue syndrome, juvenile arthritis, juvenile diabetes, scleroderma, psoriatic arthritis, Sjogren's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, idiopathic thrombocytopenic purpura (ITP), Hashimoto's disease, mixed connective tissue disease, interstitial cystitis, pernicious anemia, leukoencephalitis, alopecia areata, ankylosing spondylitis, primary biliary cirrhosis, anti-GBM nephritis, anti-TBM nephritis, anti-phospholipid syndrome, polymyalgia rheumatica, polymyositis, autoimmune Addison's disease, chronic active hepatitis, vitiligo, autoimmune hyperlipidemia, autoimmune myocarditis, temporal arteritis, autoimmune thyroid disease, axonal and neuronal neuropathies, Behçet's disease, bullous pemphigoid, allergic asthma, osteoarthritis, Chagas' disease, uveitis, chronic inflammatory demyelinating polyneuropathy (CIDP), cicatricial pemphigoid/benign mucosal pemphigoid, Cogan's syndrome, congenital heart block, Coxsackie myocarditis, demyelinating neuropathies, dermatomyositis, discoid lupus, phacoantigenic uveitis, polyarteritis nodosa, Dressler's syndrome, essential mixed cryoglobulinemia, Evan's syndrome, Goodpasture's syndrome, allergic rhinitis, Guillain-Barré syndrome, hypogammaglobulinemia, inclusion body myositis, vesiculobullous dermatosis, Wegener's granulomatosis, Ménière's disease, Lambert-Eaton syndrome, Mooren's ulcer, non-typical celiac disease, ocular cicatricial pemphigoid, pemphigus vulgaris, perivenous encephalomyelitis, post-pericardiotomy syndrome, scleritis, sperm and testicular autoimmunity, Stiff man's syndrome, subacute bacterial endocarditis (SBE), sympathetic ophthalmia, transverse myelitis and necrotizing myelopathy, type I autoimmune polyglandular syndrome, type II autoimmune polyglandular syndrome, pernicious anaemia and endometriosis.
21. The method of claim 13, wherein said autoimmune disease is insulin-dependant diabetes.
22. The method of claim 13, wherein said autoantigen is proinsulin or an immunogenic homolog, derivative, part, fragment or portion thereof.

- 36 -

23. The method of claim 22, wherein said proinsulin is of human origin.
24. The method of claim 22, wherein said proinsulin is a humanised proinsulin,  
wherein said proinsulin is derived from the group selected of pig, cow, sheep, horse, goat,  
5 mouse and rat.
25. A method for treating or preventing an autoimmune disease in a subject  
comprising,
- (a) collecting a sample of hemopoetic stem cells (HSCs) and/or hemopoetic  
10 progenitor cells (HPCs) from a subject;
  - (b) introducing into one or more HSCs and/or HPCs genetic material encoding  
said autoantigen under conditions wherein said genetic material is expressed so that the  
HSCs and/or HPCs produce said autoantigens; and
  - (c) infusing or introducing said genetically modified cells into said subject.
- 15 26. The method of claim 25, wherein said HSCs and/or HPCs undergo cytokine  
mediated mobilisation.
27. The method of claim 25, wherein said subject is selected from the group consisting  
20 of human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig,  
dog, cat, bird, chicken, bantams, geese and turkeys.
28. The method of claim 25, wherein said subject is a human.
- 25 29. The method of claim 25, wherein said HSCs and HPCs are derived from a source  
selected from bone marrow from the hipbone, bone marrow, cord blood, blood from liver,  
blood from a tissue and PBMCs.
30. The method of claim 29, wherein said HSCs and HPCs are derived from bone  
30 marrow from a hipbone.

31. The method of claim 25, wherein said autoantigen is associated with a disease selected from the group consisting of type 1 diabetes or insulin-dependent diabetes, systemic lupus, Crohn's disease, cardiomyopathy, hemolytic anemia, fibromyalgia, Graves' disease, ulcerative colitis, vasculitis, multiple sclerosis, myasthenia gravis, myositis, neutropenia, psoriasis, chronic fatigue syndrome, juvenile arthritis, juvenile diabetes, scleroderma, psoriatic arthritis, Sjogren's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, idiopathic thrombocytopenic purpura (ITP), Hashimoto's disease, mixed connective tissue disease, interstitial cystitis, pernicious anemia, leukoencephalitis, alopecia areata, ankylosing spondylitis, primary biliary cirrhosis, anti-GBM nephritis, anti-TBM nephritis, anti-phospholipid syndrome, polymyalgia rheumatica, polymyositis, autoimmune Addison's disease, chronic active hepatitis, vitiligo, autoimmune hyperlipidemia, autoimmune myocarditis, temporal arteritis, autoimmune thyroid disease, axonal and neuronal neuropathies, Behçet's disease, bullous pemphigoid, allergic asthma, osteoarthritis, Chagas' disease, uveitis, chronic inflammatory demyelinating polyneuropathy (CIDP), cicatricial pemphigoid/benign mucosal pemphigoid, Cogan's syndrome, congenital heart block, Coxsackie myocarditis, demyelinating neuropathies, dermatomyositis, discoid lupus, phacoantigenic uveitis, polyarteritis nodosa, Dressler's syndrome, essential mixed cryoglobulinemia, Evan's syndrome, Goodpasture's syndrome, allergic rhinitis, Guillain-Barre syndrome, hypogammaglobulinemia, inclusion body myositis, vesiculobullous dermatosis, Wegener's granulomatosis, Ménière's disease, Lambert-Eaton syndrome, Mooren's ulcer, non-typical celiac disease, ocular cicatricial pemphigoid, pemphigus vulgaris, perivenous encephalomyelitis, post-pericardiotomy syndrome, scleritis, sperm and testicular autoimmunity, Stiff man's syndrome, subacute bacterial endocarditis (SBE), sympathetic ophthalmia, transverse myelitis and necrotizing myelopathy, type 1 autoimmune polyglandular syndrome, type II autoimmune polyglandular syndrome, pernicious anaemia and endometriosis.

32. The method of claim 25, wherein said autoimmune disease is insulin-dependant diabetes.

- 38 -

33. The method of claim 25, wherein said autoantigen is proinsulin or an immunogenic homolog, derivative, part, fragment or portion thereof.
34. The method of claim 33, wherein said proinsulin is of human origin.
- 5 35. The method of claim 34, wherein said proinsulin is a humanized proinsulin, wherein said proinsulin is derived from a source selected from the group consisting of pig, cow, sheep, horse, goat, mouse and rat.
- 10 36. A kit in multiple compartmental form, said kit comprising a first compartment adapted to receive a source of HSCs and/or HPCs from a subject; a second compartment adapted to contain genetic material encoding an autoantigen; optionally a third or more compartments adapted to contain reagents wherein said kit comprises instructions for use comprising in a method comprising collecting a sample of hemopoetic stem cells (HSCs)
- 15 and/or hemopoetic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding said autoantigen under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said autoantigens.
- 20 37. A subject comprising an introduced APC, wherein said APC is generated using a method comprising the steps of collecting a sample of hemopoetic stem cells (HSCs) and/or hemopoetic progenitor cells (HPCs) from a subject, introducing into one or more HSCs and/or HPCs genetic material encoding said autoantigen under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said
- 25 autoantigens.
38. The use of an APC which has been genetically modified to present an autoantigen associated with a disease in the manufacture of a medicament for the treatment of an autoimmune disease, wherein said APC is generated from a HSCs and/or HPCs.

39. The use according to claim 38, wherein said APC is selected from the group consisting of a dendritic cell, B-lymphocyte, epithelial cell, monocyte and macrophage.
40. The use according to claim 2, wherein said APC is a dendritic cell.
- 5 41. The use according to claim 38, wherein said HSCs and/or HPCs are derived from a source selected from the group consisting of a human, primate, sheep, horse, cow, donkey, pig, goat, mouse, rat, guinea pig, dog, cat, chicken, bantam hen, geese and turkey.
- 10 42. The use of claim 41, wherein said HSCs and/or HPCs are derived from a human.
43. The use of claim 38, wherein said HSCs and/or HPCs are derived from a source selected from the group consisting of bone marrow from hipbone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.
- 15 44. The use of claim 38, wherein said autoantigen is associated with a disease selected from the group consisting of type 1 diabetes or insulin-dependent diabetes, systemic lupus, Crohn's disease, cardiomyopathy, hemolytic anemia, fibromyalgia, Graves' disease, ulcerative colitis, vasculitis, multiple sclerosis, myasthenia gravis, myositis, neutropenia, psoriasis, chronic fatigue syndrome, juvenile arthritis, juvenile diabetes, scleroderma, psoriatic arthritis, Sjogren's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, idiopathic thrombocytopenic purpura (ITP), Hashimoto's disease, mixed connective tissue disease, interstitial cystitis, pernicious anemia, leukoencephalitis, alopecia areata, ankylosing spondylitis, primary biliary cirrhosis, anti-GBM nephritis, anti-TBM nephritis, anti-phospholipid syndrome, polymyalgia rheumatica, polymyositis, autoimmune Addison's disease, chronic active hepatitis, vitiligo, autoimmune hyperlipidemia, autoimmune myocarditis, temporal arteritis, autoimmune thyroid disease, axonal and neuronal neuropathies, Behçet's disease, bullous pemphigoid, allergic asthma, osteoarthritis, Chagas' disease, uveitis, chronic inflammatory demyelinating
- 25 30 polynuropathy (CIDP), cicatricial pemphigoid/benign mucosal pemphigoid, Cogan's syndrome, congenital heart block, Coxsackie myocarditis, demyelinating neuropathies,



- 40 -

- dermatomyositis, discoid lupus, phacoantigenic uveitis, polyarteritis nodosa, Dressler's syndrome, essential mixed cryoglobulinemia, Evan's syndrome, Goodpasture's syndrome, allergic rhinitis, Guillain-Barré syndrome, hypogammaglobulinemia, inclusion body myositis, vesiculobullous dermatosis, Wegener's granulomatosis, Ménière's disease,
- 5 Lambert-Eaton syndrome, Mooren's ulcer, non-typical celiac disease, ocular cicatricial pemphigoid, pemphigus vulgaris, perivenous encephalomyelitis, post-pericardiotomy syndrome, scleritis, sperm and testicular autoimmunity, Stiff man's syndrome, subacute bacterial endocarditis (SBE), sympathetic ophthalmia, transverse myelitis and necrotizing myelopathy, type I autoimmune polyglandular syndrome, type II autoimmune
- 10 polyglandular syndrome, pernicious anaemia and endometriosis.
45. The use of claim 38, wherein said autoimmune disease is insulin-dependant diabetes.
- 15 46. The use of claim 38, wherein said autoantigen is proinsulin or an immunogenic homolog, derivative, part, fragment or portion thereof.
47. The use of claim 46, wherein said proinsulin is of human origin.
- 20 48. The use of claim 38, wherein said proinsulin is a humanized proinsulin, wherein said proinsulin is derived from a source selected from the group consisting of pig, cow, sheep, horse, goat, mouse and rat.

## CLAIMS

1. A method of preventing or treating insulin-dependent diabetes in a subject comprising introducing into said subject an APC which presents pro-insulin associated with an autoimmune disease, said method comprising collecting a sample of hemopoietic stem cells (HSCs) and/or hemopoietic progenitor cells (HPCs) from said subject, introducing into one or more HSCs and/or HPCs genetic material encoding said pro-insulin or an immunogenic homolog, part, fragment or portion thereof under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said pro-insulin or an immunogenic homolog, part, fragment or portion thereof.
2. The method of claim 1, wherein said APC is selected from a dendritic cell, B-lymphocyte, epithelial cell, monocyte and macrophage.
3. The method of claim 2, wherein said APC is a dendritic cell.
4. The method of claim 1, wherein said subject is selected from the group consisting of a human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig, dog, cat, bird, chicken, bantams, geese and turkeys.
5. The method of claim 1, wherein said subject is a human.
6. The method of claim 1, wherein said cell is derived from bone marrow from the hip bone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.
7. The method of claim 6, wherein said cell is derived from bone marrow from a hip bone.
8. The method of claim 1, wherein said proinsulin is of human origin.

- 33 -

9. The method of claim 1, wherein said proinsulin is a humanised proinsulin, wherein said proinsulin is derived from the group selected of pig, cow, sheep, horse, goat, mouse and rat.

10. A method for treating or preventing insulin-dependent diabetes in a subject comprising,

- (a) collecting a sample of hemopoietic stem cells (HSCs) and/or hemopoietic progenitor cells (HPCs) from a subject;
- (b) introducing into one or more HSCs and/or HPCs genetic material encoding pro-insulin or an immunogenic homolog, part, fragment or portion thereof under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said pro-insulin or an immunogenic homolog, part, fragment or portion thereof; and
- (c) infusing or introducing said genetically modified cells into said subject.

11. The method of claim 10, wherein said HSCs and/or HPCs undergo cytokine mediated mobilisation.

12. The method of claim 10, wherein said subject is selected from the group consisting of human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig, dog, cat, bird, chicken, bantams, geese and turkeys.



13. The method of claim 10, wherein said subject is a human.

14. The method of claim 10, wherein said HSCs and HPCs are derived from a source selected from bone marrow from the hipbone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.

15. The method of claim 14, wherein said HSCs and HPCs are derived from bone marrow from a hipbone.

16. The method of claim 10, wherein said proinsulin is of human origin.
17. The method of claim 10, wherein said proinsulin is a humanized proinsulin, wherein said proinsulin is derived from a source selected from the group consisting of pig, cow, sheep, horse, goat, mouse and rat.
18. Use of an APC which has been genetically modified to present pro-insulin or an immunogenic homolog, part, fragment or portion thereof associated with insulin-dependent diabetes in the manufacture of a medicament for the treatment of insulin-dependent diabetes
19. The use of claim 18, wherein said APC is selected from the group consisting of a dendritic cell, B-lymphocyte, epithelial cell, monocyte and macrophage.
20. The use of claim 18, wherein said APC is a dendritic cell.
21. The use of claim 18, wherein said HSCs and/or HPCs are derived from a source selected from the group consisting of a human, primate, sheep, horse, cow, donkey, pig, goat, mouse, rat, guinea pig, dog, cat, chicken, bantam hen, geese and turkey.
22. The use of claim 21, wherein said HSCs and/or HPCs are derived from a human.
23. The use of claim 18, wherein said HSCs and/or HPCs are derived from a source selected from the group consisting of bone marrow from hipbone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.
24. The use of claim 18, wherein said proinsulin is of human origin.
25. The use of claim 18, wherein said proinsulin is a humanized proinsulin, wherein said proinsulin is derived from a source selected from the group consisting of pig, cow, sheep, horse, goat, mouse and rat.

1/11

**Figure 1A****Figure 1B**




Figure 2A




Figure 2B




Figure 2C






Figure 2D

3/11

**Figure 3A****Figure 3B**

4/11





Figure 4A

	8 weeks post-BMT			16 weeks post-BMT		
	NOD BMT	NOD-PI BMT	NOD	NOD BMT	NOD-PI BMT	NOD
CD3 <sup>+</sup>	38.6 ± 7.3	35.6 ± 6.0	38.7 ± 13.5	53.8 ± 13.4	43.8 ± 14.4	57.3 ± 13.5
CD4 <sup>+</sup>	29.1 ± 7.1	29.3 ± 3.1	27.5 ± 5.4	38.7 ± 12.0	32.7 ± 12.0	39.4 ± 11.8
CD8 <sup>+</sup>	8.8 ± 2.3	8.9 ± 1.3	15.8 ± 5.1	14.2 ± 3.2	11.5 ± 3.0	16.2 ± 1.2
B220 <sup>+</sup>	14.3 ± 4.8	9.1 ± 3.2	15.5 ± 2.5	16.8 ± 5.5	17.4 ± 4.4	19.7 ± 2.6
CD11b <sup>+</sup>	35.3 ± 12.1	30.6 ± 10.5	21.9 ± 11.6	22.3 ± 16.2	30.4 ± 15.3	21.8 ± 20.3
n =	19	6	6	18	13	6

Figure 4B



5/11

**Figure 5**




Figure 6

7/11




Figure 7




Figure 8

Treated @ 4wks




Figure 9

10/11

Treated @ 4wks (1.8 x10<sup>6</sup> CD11c-depleted I.V.)





Figure 10

11/11

**Figure 11**

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/AU03/01212**

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int. Cl. <sup>7</sup> : C12N 5/08, 5/10; A61K 48/000, 35/14		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) <b>SEE ELECTRONIC DATABASES BELOW</b>		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched <b>SEE ELECTRONIC DATABASES BELOW</b>		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS MedLine CA: hem(at)opoietic stem cells, autoimmunity, tolerance, auto/self antigen		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	Stephoe RJ et al. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest, 2003. 111(9): 1357-63	All
X, P	Alderuccio Frank; Murphy Kim; Toh Ban Hock. Stem cells engineered to express self-antigen to treat autoimmunity. Trends Immunol, (2003 Apr) 24(4) 176-80.	All
X	Kawahata K et al. Peripheral tolerance to a nuclear autoantigen: dendritic cells expressing a nuclear autoantigen lead to persistent anergic state of CD4 <sup>+</sup> autoreactive T cells after proliferation. J Immunol, 2002. 168: 1103-1112.	1-9,13-20, 25-31,36-44
Y		10-12, 21-24, 32-34.
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search <b>8 October 2003</b>		Date of mailing of the international search report <b>31 OCT 2003</b>
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  <b>Gillian Allen</b> Telephone No : (02) 6283 2266



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01212

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/25398 A2 (BIOTRANSPLANT INCORPORATED) 12 April 2001	All
Y	Peters, T. R.; Bodine, D. M.; McDonagh, K. T.; Lovett-Racke, A.; McFarland, H. F.; McFarlin, D. E.; Nienhuis, A. W.; Racke, M. K.. Retrovirus mediated gene transfer of the self antigen MBP into the bone marrow of mice alters resistance to experimental autoimmune encephalomyelitis. Journal of Neuroimmunology (2000), 103(1), 51-62	All
Y	Steinman RM et al. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Nat Acad Sci USA, Jan 2002. 99(1): 351-59.	All
A	Burt RK et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure. Blood, Feb 2002. 99(3): 768-84.	
A	Burt Richard K; Oyama Yu; Traynor Ann; Kenyon Norma S. Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis. Autoimmun Rev, (2002 May) 1 (3) 133-8.	
A	Wu Tao; Levay-Young Brett; Heuss Neal; Sozen Hakan; Kirchhof Nicole; Sutherland David E R; Hering Bernhard; Guo Zhiguang. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation, (2002 Jul 15) 74 (1) 22-7.	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU03/01212

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
WO 01/25398 A2	CA 2385750 A1 AU 77406/00 A
END OF ANNEX	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**